Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing

Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing

Source: 
Xconomy
snippet: 

By early September Biogen—plus the many scientists, patients, and investors following the saga of its controversial Alzheimer’s drug aducanamab—should know whether the FDA plans to review the Cambridge, MA biotech’s experimental brain disease treatment.